CellSight Technologies, Inc.
“CellSight is proud to support and excited to participate in the FNIH iRelate project, which seeks to understand the utility of PET imaging in comprehensive characterization of the T cell milieu in the tumor microenvironment. This collaborative initiative resonates with CellSight’s patient-centered ethos, and represents an important step towards the development of predictive imaging biomarkers.”
Jelena Levi, PhD
Chief Scientific Officer
CellSight Technologies, Inc.
Boehringer Ingelheim
“At Boehringer Ingelheim we are driven to develop first-in-class treatments that activate the patients immune system to fight cancer cells. An in depth understanding of the engagement and activation of CD8+ T cells within the tumor microenvironment is crucial as they are the key drivers of an anti-tumor response. Imaging biomarkers will play a vital role for a comprehensive assessment of the intricate tumor microenvironments and its heterogeneity within and between tumor lesions as well as the specific contribution of the patients’ immune system. The iRelate study is an important initiative aiming to minimize the need for biopsies and improving patient quality of life providing information on the mechanism of action of immunotherapeutic drugs derived from non-invasive assessments. Pre-competitive projects within the FNIH Biomarker Consortium are very important to foster further validation and integration of imaging biomarkers into drug development.”
Vittoria Zinzalla, PhD
Global Head of Oncology Translational Medicine and Clinical Pharmacology
Boehringer Ingelheim